Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

European Union support for the Lebanese Healthcare System reaches €173 million

18 December 2018 - The European Union has renewed its commitment to strengthen the Lebanese health care system and secure access to chronic medications, vaccines and essential medical commodities to the most vulnerable population in Lebanon. Through an additional contribution of 19 million Euro from the EU Regional Trust Fund in response to the Syrian crisis, UNICEF and WHO will be able to support to people in need living in Lebanon by ensuring provision of primary healthcare services and strengthening the health system.
 
The additional funding was announced today during a joint press conference headed by the Minister of Public Health, Ghassan Hasbani, EU Ambassador Christina Lassen, WHO representative Dr. Imane Shankiti, and UNICEF Representative, Tanya Chapuisat. The donation is part of a package of support of 173 million Euro which the European Union has invested in the health sector to strengthen the system and to help meet the basic health needs of both Lebanese citizens and Syrian refugees in a time of great pressure on service delivery and health infrastructure.
 
“We thank the commitment of the European Union and the support of the World Health Organization and UNICEF in strengthening the healthcare system to meet the needs of both Lebanese and Syrian refugees,” said Minister Hasbany.
 
EU Ambassador Lassen highlighted that "the projects we are launching today are part of a 173 million Euro health package that includes primary and secondary healthcare and aims at achieving quality, affordable and accessible health services for everyone in need in Lebanon".
 
“The generous support of the EU to the health system has sealed a long-standing partnership between the MOPH, WHO and UNICEF, and ensured that health services were of good quality, and that outbreaks and health risks are identified and acted upon early enough” said Imane Shankiti, WHO representative. “Reinforcing the health system capacity, along with filling critical health services with EU support ensured that no patient in need for health care was left behind”.
 
“The strong partnership we have with the EU, the ministry of Public Health and WHO has ensured that every child in Lebanon has access to quality vaccines to remain safe from outbreaks of preventable diseases,” said Tanya Chapuisat, UNICEF Representative to Lebanon. “Through EU funding we are able to save lives and strengthen systems to shape a better future for children”.
 
 
    3
ATC Name B/G Ingredients Dosage Form Price
B05CX01 GLUCOSE INJ. G Glucose - 10g/20ml 50% Injectable solution 5,038,066 L.L
L03AX13 GLITAXON G Glatiramer acetate - 20mg/ml 20mg/ml Injectable solution 10,146,988 L.L
A10AE04 GLARTUS BioTech Insulin glargine - 100U/ml 100U/ml Injectable solution 1,346,530 L.L
A03AB02 GLYCOPYRROLATE B Glycopyronium Bromide - 0.2mg/ml 0.2mg/ml Injectable solution 7,238,185 L.L
B05AA06 GELASPAN B Gelatine, succinylated - 4% 4% Injectable solution 9,107,572 L.L
G03GA05 GONAL-f BioHuman Follitropin alfa - 900IU/1.5ml 66mcg/1.5ml Injectable solution 29,625,401 L.L
G03GA05 GONAL-f BioHuman Follitropin alfa - 450IU/0.75ml 450IU/0.75ml Injectable solution 14,813,959 L.L
G03GA05 GONAL-f BioHuman Follitropin alfa - 300IU/0.5ml 300IU/0.5ml Injectable solution 10,305,698 L.L
J07BB01 GC FLU QUADRIVALENT INFLUENZA VACCINE G Influenza vaccine inactivated (split virion, purified, quadrivalent) (H1N1, H3N2,BVR-26, B/Phuket/3073/2013) - 15mcg/4strains/0.5ml Injectable suspension 791,523 L.L
J07BM03 GARDASIL 9 HUMAN PAPILLOMAVIRUS 9- VALENT VACCINE RECOMBINANT B Papillomavirus (human type 6) - 30mcg/0.5ml, Papillomavirus (human type 11) - 40mcg/0.5ml, Papillomavirus (human type 16) - 60mcg/0.5ml, Papillomavirus (human type 18) - 40mcg/0.5ml, Papillomavirus (human type 31) - 20mcg/0.5ml, Papillomavirus (human type 33) - 20mcg/0.5ml, Papillomavirus (human type 45) - 20mcg/0.5ml, Papillomavirus (human type 52) - 20mcg/0.5ml, Papillomavirus (human type 58) - 20mcg/0.5ml Injectable suspension 14,139,396 L.L
A02BX13 GAVISCON B Sodium alginate - 500mg/10ml, Sodium bicarbonate - 267mg/10ml, Calcium (carbonate) - 160mg/10ml Liquid 295,645 L.L
D02AX GLYCERINE G Glycerol - Liquid 163,821 L.L
A04AD GRAVOL B Dimenhydrinate - 15mg/5ml 15mg/5ml Liquid 258,018 L.L
P03AB02 GAMMA BENZENE HEXACHLORIDE G Lindane - 1% 1% Lotion 167,660 L.L
G01AF04 GYNO-MIKOZAL G Miconazole nitrate - 200mg 200mg Ovule 503,941 L.L
G01AF04 GYNO-MIKOZAL G Miconazole nitrate - 400mg 400mg Ovule 302,365 L.L
G03DA04 GESTA 400 G Progesterone - 400mg 400mg Pessary 1,083,137 L.L
A02BX13 GAVISCON INFANT B Sodium alginate - 225mg, Magnesium alginate - 87.5mg Powder for suspension 710,893 L.L
P03AB02 GAMMA BENZENE HEXACHLORIDE G Lindane - 1% 1% Shampoo 195,817 L.L
P03AB02 GAMMAPHARM G Lindane - 1% 1% Shampoo 195,817 L.L
A04AD GRAVOL B Dimenhydrinate - 100mg 100mg Suppository 294,302 L.L
A02BX13 GAVISCON ADVANCE ANISEED FLAVOR B Sodium alginate - 1000mg/10ml, Potassium hydrogen carbonate - 200mg/10ml Suspension 514,692 L.L
A02BX13 GAVISCON DOUBLE ACTION MINT B Sodium alginate - 500mg/10ml, Sodium bicarbonate - 213mg/10ml, Calcium (carbonate) - 325mg/10ml Suspension 542,912 L.L
A02BX13 GAVISCON DOUBLE ACTION B Sodium alginate - 500mg, Sodium bicarbonate - 213mg, Calcium (carbonate) - 325mg Suspension 517,379 L.L
A02BX13 GAVISCON PEPPERMINT LIQUID B Sodium alginate - 250mg/10ml, Sodium bicarbonate - 133.5mg/10ml, Calcium (carbonate) - 80mg/10ml Suspension 393,746 L.L
A10BF01 GLUFIX G Acarbose - 50mg 50mg Tablet 1,294,120 L.L
A10BH02 GALVUS B Vildagliptin - 50mg 50mg Tablet 950,097 L.L
A10BH02 GLUNORM G Vildagliptin - 50mg 50mg Tablet 611,448 L.L
N03AX12 GABATREX G Gabapentin - 600mg 600mg Tablet 3,132,497 L.L
A10BA02 GLUCOBAS G Metformin - 850mg 850mg Tablet 217,575 L.L
    3
Sitemap
© Copyrights reserved to Ministry of Public Health 2025